The last major advance in the treatment of metastatic bladder cancer (BC) took place in 1997 with the advent of gemcitabine. Despite this advance, visceral metastases are usually fatal. The overall goal of the proposed studies is to develop small molecule inhibitors that block a critical node in the metastatic process. We found that Rai GTPases serve as the molecular switches of a therapeutically tractable signaling pathway that allows UC cells to grow in the lung, the most common visceral metastatic site. The clinical significance of this pathway and validity of Rai as a therapeutic target is supported by finding that high Rai expression in tumors places patients at higher risk for metastasis and the requirement of Rai expression for lung metastasis to occur in animal models of UC. Our Guiding Hypothesis for this application is that small molecules targeting Rai provide effective therapy for metastatic UC. With support from the MD Anderson Bladder SPORE Developmental Research Program (DRP), we evaluated >500K compounds for their ability to bind RalA or RalB in computational and combinatorial screens and selected 99 """"""""hits"""""""". These were evaluated in a series of secondary assays allowing us to select Rai Binding Compound (RUC)8 and 10 to be pursued in this application. RUC8 and 10 were selected because they: 1) inhibit RalA to RalBPI binding in human UC cells and RalA induced spreading in murine embryo fibroblasts;2) inhibit in vitro monolayer growth (IC50 0.5-1.9 pM) of human UC cells;3) bind RalB directly by nuclear magnetic resonance (NMR) spectroscopy;and 4) have good pharmacokinetic (PK) properties in mice (Cmax 1.3-23 pM, T1/2 3.7-4.6 hrs). To develop this novel class of agents we propose the following Specific Aims:
Aim 1 : Characterize higher potency 2""""""""^* generation compounds based on RUC8 and 10 using medicinal chemistry, computational fragment-based design, and similarity search of chemical databases. In the unlikely situation that higher potency compounds are not found in Aim 1, we will pursue Aim 2 and 3 using RUC8 and 10, given their adequate IC50 and in vivo PK.
Aim 2 : Evaluate 2"""""""""""""""" generation compounds for their in vivo therapeutic efficacy in novel human UC models of visceral metastasis.
Aim 3 : Develop predictive biomarkers of response to antlRal therapeutics in human tissues that will position us for Phase 1 trials by end of this project. Documented interest by Astra Zeneca in our work improves overall chances for success in translating our novel Rai inhibitors into the clinical setting as anticancer therapeutics.
Inhibition of GTPases and its translation into viable cancer therapeutics has been unsuccessfully sought since discovery of Ras in 1982. Our preliminary work demonstrates first in class inhibitors of the Rai GTPase which may constitute the first significant therapeutic advance in metastatic bladder cancer since 1997. Since Rai GTPases are also important drivers of human pancreatic and prostate cancer growth and metastasis, this work has the potential to provide an effective therapeutic for several major cancer types.
|Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135|
|Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804|
|Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :|
|Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105|
|Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44|
|Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65|
|Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :|
|Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416|
|Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946|
|Metcalfe, Michael J; Ferguson, James E; Li, Roger et al. (2017) Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3:577-583|
Showing the most recent 10 out of 247 publications